InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

InflaRx (Nasdaq: IFRX) reported it has regained compliance with Nasdaq's minimum bid price requirement under Rule 5450(a)(1).

Rhea-AI Summary

InflaRx (Nasdaq: IFRX) reported it has regained compliance with Nasdaq's minimum bid price requirement under Rule 5450(a)(1). The closing bid price was at least $1.00 for 10 consecutive business days from April 13, 2026 to April 24, 2026, and Nasdaq closed the matter.

The company reiterated its lead programs, izicopan and vilobelimab, and listed investor contacts and subsidiaries.

Positive

• Regained Nasdaq compliance: closing bid ≥ $1.00 for 10 consecutive business days
• Matter closed by Nasdaq Listing Qualifications Department as of April 27, 2026

Negative

• None.

Argus Apr 28 session

+3.73% close to close Open Argus

Details

News Market Reaction – IFRX

In the Apr 28 session, IFRX gained 3.73%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement confirms that InflaRx restored compliance with Nasdaq’s Minimum Bid Price Requirem...

Analysis

This announcement confirms that InflaRx restored compliance with Nasdaq’s Minimum Bid Price Requirement by maintaining a closing bid of at least $1.00 for 10 consecutive business days. It removes near‑term listing risk while the company continues to advance izicopan and vilobelimab. In context of prior updates on trial data and cash runway, investors may focus on future clinical milestones, further regulatory developments, and any changes in capital structure or operating guidance.

Key Figures

Nasdaq minimum bid: $1.00 per share Compliance period: 10 consecutive business days Founding year: 2007 +5 more

Nasdaq minimum bid

$1.00 per share

Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

Compliance period

10 consecutive business days

Closing bid at or above $1.00 from April 13–24, 2026

Founding year

2007

InflaRx founding date per company description

Current share price

$1.61

IFRX price before publication, up 8.78% in 24h

52-week high

$1.94

IFRX 52-week high vs pre-news price

52-week low

$0.7113

IFRX 52-week low vs pre-news price

Market cap

$106,993,431

Pre-news market capitalization

200-day moving average

$1.11

IFRX trading above its 200-day MA

Historical Context

5 past events · Latest: Apr 09

5 events

1. Apr 09

   Izicopan mechanistic data

   24h Move

   +8.4%

   New in vitro data supporting favorable izicopan safety and PK/PD profile.

2. Mar 31

   Conference participation

   24h Move

   +7.5%

   Announcement of participation in Raymond James biotech symposium and pipeline overview.

3. Mar 30

   Vilobelimab Phase 3 data

   24h Move

   -8.8%

   Phase 3 PG trial stopped for futility despite some efficacy and safety signals.

4. Mar 19

   Full-year 2025 results

   24h Move

   +3.4%

   2025 financials, Phase 2a izicopan data, and cash runway to mid‑2027.

5. Mar 18

   AAD presentation notice

   24h Move

   -3.6%

   Announcement of upcoming late-breaker vilobelimab Phase 3 presentation at AAD 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

minimum bid price requirement, nasdaq listing rule 5450(a)(1), complement system, c5a, +4 more

8 terms

minimum bid price requirement regulatory

"regained compliance with Nasdaq’s minimum bid price requirement set forth under"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

nasdaq listing rule 5450(a)(1) regulatory

"requirement set forth under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”)"

Nasdaq Listing Rule 5450(a)(1) is a continued-listing standard that sets a minimum share price companies must maintain to remain listed on the Nasdaq market—commonly a $1.00 per-share threshold. Investors care because falling below that floor can trigger a compliance review and possible delisting, which is like failing a minimum grade and losing access to the public market; delisting can reduce liquidity, visibility and the ability to raise capital.

complement system medical

"pioneering anti-inflammatory therapeutics by targeting the complement system (the “Company”)"

The complement system is a set of proteins in the blood that act together like a security alarm and cleanup crew for the body’s immune system: they detect threats, tag invaders for removal, and help destroy harmful cells. Investors should care because drugs or diagnostics that target or measure this system can affect treatment effectiveness, safety profiles, and market potential for therapies in immune, inflammatory, and rare disease areas.

c5a medical

"inhibitors of the complement activation factor C5a and its receptor, C5aR."

C5a is a small protein produced by the immune system that acts like an alarm bell, signaling and attracting immune cells to sites of infection or injury and triggering inflammation. Investors care because excessive or uncontrolled C5a activity is linked to many inflammatory and autoimmune diseases, making it a common target for drugs and diagnostics; treatments that block or measure C5a can affect clinical outcomes, regulatory approval prospects, and commercial value in biotech and pharmaceutical portfolios.

c5ar medical

"inhibitors of the complement activation factor C5a and its receptor, C5aR."

C5aR is a protein on the surface of immune cells that senses and responds to a small immune signaling molecule called C5a; when activated it acts like a doorbell that calls immune cells and ramps up inflammation. It matters to investors because drugs that block or modulate this receptor can reduce harmful inflammation in diseases, so clinical trial results, approvals, or setbacks for C5aR-targeting therapies can materially affect a biotech’s value and market prospects.

monoclonal antibody medical

"vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

phase 2a medical

"therapeutic potential in Phase 1 and Phase 2a clinical studies."

Phase 2a is an early stage in testing a new medical treatment or drug, where the main goal is to assess its safety and find the right dosage. For investors, this stage indicates whether the treatment shows initial promise before moving on to larger, more definitive studies; progress here can influence expectations for future development and potential success.

phase 3 medical

"has developed vilobelimab, a novel, intravenously delivered... clinical activity in multiple clinical studies."

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

JENA, Germany, April 28, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the “Company”), today announced that it has received a written notice (the “Notice”), dated April 27, 2026, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with Nasdaq’s minimum bid price requirement set forth under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”).

According to the Notice, the Company regained compliance with the Minimum Bid Price Requirement because the closing bid price of the Company’s ordinary shares has been $1.00 per share or greater for 10 consecutive business days, from April 13, 2026 to April 24, 2026, and the matter is now closed.

About InflaRx N.V.

InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The Company is developing izicopan for the treatment of several inflammatory diseases, including hidradenitis suppurativa. InflaRx also has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.

InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).

Contacts:

InflaRx N.V.	MC Services AG
Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de	Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others, statements regarding our compliance with the Minimum Bid Price Rule and listing or trading of our ordinary shares. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the headings, “Risk factors” and “Cautionary statement regarding forward looking statements”, in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How did InflaRx (IFRX) regain Nasdaq compliance on April 27, 2026?

InflaRx regained compliance because its closing bid price was at least $1.00 for 10 consecutive business days. According to the company, the 10-day period ran from April 13 to April 24, 2026, after which Nasdaq closed the matter.

What Nasdaq rule did InflaRx (IFRX) meet to regain compliance?

InflaRx met Nasdaq Listing Rule 5450(a)(1), the minimum bid price requirement. According to the company, this rule requires a closing bid of at least $1.00 sustained for 10 consecutive business days.

Does the Nasdaq notice for InflaRx (IFRX) mean its listing is secure?

The Nasdaq notice states the company regained compliance and the specific deficiency is closed. According to the company, this resolves the minimum bid price deficiency but does not comment on other listing criteria or future compliance.

When did the closing bid price meet the $1.00 threshold for InflaRx (IFRX)?

The closing bid price met the $1.00 threshold for 10 consecutive business days from April 13, 2026 through April 24, 2026. According to the company, Nasdaq provided written notice dated April 27, 2026 confirming compliance.

What programs and locations did InflaRx (IFRX) highlight in the announcement?

The company highlighted lead programs izicopan and vilobelimab and its offices in Jena, Munich, and Ann Arbor. According to the company, izicopan has completed Phase 1 and Phase 2a studies and vilobelimab showed clinical activity.